Aastrom Biosciences, Inc. Announces Amendment of Series B Preferred Stock Certificate of Designations, Preferences and Rights

Published: Aug 13, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ANN ARBOR, Mich., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it has entered into an agreement with Eastern Capital Limited to amend the Company's Series B Preferred Stock Certificate of Designations, Preferences and Rights to, among other things, amend the treatment of the Company's Series B-1 Non-Voting Preferred Stock and Series B-2 Voting Preferred Stock. As a result of the amendment, the Series B-2 Shares will be reclassified from mezzanine equity to shareholders' equity on the Company's balance sheet, increasing shareholders' equity by $37.7 million.

Help employers find you! Check out all the jobs and post your resume.

Back to news